Roche Tamiflu Prevents Flu In More Than 99% Of Frail Elderly - ICAAC
Executive Summary
Prophylactic use of Roche's Tamiflu (oseltamivir) reduced the incidence of influenza in an elderly nursing home population to less than 1%, according to preliminary results from a once-daily prevention study presented by Frederick Hayden, MD, University of Virginia, Sept. 27 at the Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco.
You may also be interested in...
Gilead/Roche Tamiflu Has Two-Thirds Of Flu Market, Gilead Tells BIO
Tamiflu is garnering about two-thirds of U.S. neuraminidase inhibitor prescriptions as the 1999-2000 flu season winds down, Gilead CEO John Martin, PhD, said Feb. 16 at the Biotechnology Industry Organization CEO and Investor Conference in New York City.
Gilead/Roche Tamiflu Has Two-Thirds Of Flu Market, Gilead Tells BIO
Tamiflu is garnering about two-thirds of U.S. neuraminidase inhibitor prescriptions as the 1999-2000 flu season winds down, Gilead CEO John Martin, PhD, said Feb. 16 at the Biotechnology Industry Organization CEO and Investor Conference in New York City.
Roche Tamiflu Reduces Flu Symptom Severity 40% - Swiss Label
Roche's oral influenza therapy Tamiflu (oseltamivir) was associated with a 40% reduction in the severity of flu symptoms in patients with verified influenza compared to placebo, Swiss labeling reports.